Vabicaserin

DB12071InvestigationalSmall molecule

Vabicaserin has been used in trials studying the health services research and treatment of Schizophrenia.

Mechanism: Pharmacologically active on 5-hydroxytryptamine receptor 2A, 5-hydroxytryptamine receptor 2C, and 5-hydroxytryptamine receptor 2B
Curator reviewed
Formula / weight: C₁₅H₂₀N₂ · 228.339 g/mol (avg)

Resolves to

Compound

Structure

InChIKeyNPTIPEQJIDTVKR-STQMWFEESA-NSMILESC1C[C@H]2CN3CCNCC4=C3C(=CC=C4)[C@H]2C1

Targets

What you can answer from here — as of September 21, 2026

3Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

707Drug interactionsStructured to mechanism, not free text

3Clinical trialsPhase, status and sponsor resolved per trial

8+ReferencesStructured and connected to the statements they support

Which drugs share a target with Vabicaserin, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.